Dr. Morris on choosing between FDA-approved PSMA-PET imaging agents

Michael J. Morris, MD, discusses the choice between the 2 FDA-approved PSMA-PET imaging agents—and piflufolastat F 18 (18F-DCFPyL; Pylarify) and Gallium 68 PSMA-11 (Ga 68 PSMA-11)—for managing patients with prostate cancer.

Morris a medical oncologist and section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, was the lead study author on the VISION trial (J Clin Oncol 39, 2021 [suppl 15; abstr LBA4], which explored the PSMA-targeted therapy 177Lu-PSMA-617 in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The study used Ga 68 PSMA-11 to determine PSMA positivity. Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone (J Clin Oncol 39, 2021 [suppl 15; abstr LBA4]).